Composition
Moxflo 0.5% Eye Drops: Each ml contains Moxifloxacin Hydrochloride USP equivalent to Moxifloxacin 5 mg.
Preservative: Benzalkonium Chloride Solution BP 0.04%
Pharmacology
Moxflo (Moxifloxacin) is a 4th generation fluorinated quinolone. Moxifloxacin shows antibacterial activity by inhibiting the bacterial enzyme topoisomerase-II (DNA gyrase) and topoisomerase-IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase-IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.
Indication
Moxflo (Moxifloxacin) ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms-
Aerobic gram-positive bacteria: Streptococcus pneumoniae, Staphylococcus aureus, Corynebacterium species, Micrococcus luteus.
Aerobic gram-negative bacteria: Acinetobacter lwoffii, Haemophilus influenzae, Haemophilus parainfluenzae.
Dosage and Administration
One drop in the affected eye(s) 3 times daily for 7 days,
or, as directed by the registered physician.
Contraindication
Moxifloxacin is contraindicated in patients with a history of hypersensitivity to Moxifloxacin, to other quinolones or to any of components in this medication.
Warning & Precaution
As Moxifloxacin is an antibiotic fulfill the course of the medicine according to the advice of the physician. Prolonged use may result in overgrowth of non-susceptible organisms, including fungi like with other anti-infective. If super-infection occurs, discontinue use and introduce alternative therapy.
Side Effects
The most frequently reported ocular side effects were conjunctivitis, decreased visual acuity, dry eye, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage and tearing. These events occurred in approximately (1-6)% of patients.
Use in Pregnancy & Lactation
There are no adequate and well-controlled studies in pregnant women. Moxifloxacin ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Moxifloxacin has not been measured in human milk, although it can be presumed to be excreted in human milk. So caution should be exercised when administered to a lactating mother.
Use in Paediatric
The safety and effectiveness of Moxifloxacin eye drops in below one year of age was not proven earlier. However, several latest clinical studies show that the drug can be used safely in children even younger than one month of age.
Drug Interaction
Drug-drug interaction studies have not been conducted with Moxifloxacin ophthalmic solution. In vitro studies indicate that Moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2 indicating that Moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isoenzymes.
Storage
Store below 25°C, protect from light and moisture. Keep out of the reach of children. Do not use longer than 30 days after first opening.
Packaging
Moxflo 0.5% Eye Drops: Each flow control dropper bottle contains 5 ml Sterile Eye Drops
